References
Moreland LW, Alten R, Van den BoschF, et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double blind, placebo controlled clinical trial evaluating CTLA-4Iq and LEA294 eighty five days after the first infusion. Arthritis Rheum 2002, 46:1470–1479.
Teng GG, Turkiewicz AM, Moreland LW: Abatacept: A costimulatory inhibitory for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005, 5:1245–1254.
Bluestone JA, St Clair EW, Turka LA: CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006, 24:233–238.
Edwards JC, Cambridge G: Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology 2005, 44:151–156.
Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572–2581.
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613–620.
Rights and permissions
About this article
Cite this article
Moreland, L. Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate. Curr Rheumatol Rep 8, 368 (2006). https://doi.org/10.1007/s11926-006-0067-6
Issue Date:
DOI: https://doi.org/10.1007/s11926-006-0067-6